ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)

被引：11
|
作者：
Vinik, Aaron
Wolin, Edward M.
Audry, Helene
Gomez-Panzani, Edda L.
机构：
[1] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Ipsen, Boulougne Billancourt, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.268
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
268
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic Behavior of Lanreotide Autogel in Patients with Carcinoid Neuroendocrine Tumors
    Ramis, J.
    Cendros, J. M.
    Peraire, C.
    Obach, R.
    Lesage, C.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 133 - 134
  • [22] Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
    Wolin E.M.
    Manon A.
    Chassaing C.
    Lewis A.
    Bertocchi L.
    Richard J.
    Phan A.T.
    Journal of Gastrointestinal Cancer, 2016, 47 (4) : 366 - 374
  • [23] Safety and Tolerability of Lanreotide Autogel/Depot in Patients With Neuroendocrine Tumors: Pooled Analysis of Clinical Studies
    Phan, Alexandria T.
    Wolin, Edward M.
    Fisher, George A., Jr.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Liyanage, Nilani
    Mirakhur, Beloo
    Braun, Stephan
    Caplin, Martyn E.
    Vinik, Aaron I.
    PANCREAS, 2018, 47 (03) : 351 - 351
  • [24] Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study
    Baudin, E.
    Hoersch, D.
    Singh, S.
    Caplin, M.
    Ferone, D.
    Wolin, E.
    Capdevila, J.
    Buikhuisen, W.
    Raderer, M.
    Houchard, A.
    Thanh, Truong X. M.
    Reidy-Lagunes, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 165 - 165
  • [26] Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
    Pavel, M.
    Dromain, C.
    Massien, C.
    Houchard, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) With Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients With Carcinoid Syndrome (CS): Results From the SymNET Study
    Ruszniewski, Philippe
    Caplin, Martyn E.
    Valle, Juan W.
    Lombard-Bohas, Catherine
    Poston, Graeme
    Perros, Petros
    Holubec, Lubos
    Delle Fave, Gianfranco
    Smith, Denis
    Niccoli, Patricia
    Maisonobe, Pascal
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 357 - 358
  • [30] Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.
    Reidy, Diane Lauren
    Kulke, Matthew H.
    Wolin, Edward M.
    Singh, Simron
    Ferone, Diego
    Mirakhur, Beloo
    Massien, Christine
    Houchard, Aude
    Caplin, Martyn E.
    Baudin, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345